All manuscripts submitted to ARP will undergo a thorough peer-review process by physicians and scientists with relevant expertise. The Editorial Board [5] of ARP is committed to ensure a fair but reasonably expeditious peerreview process, followed by immediate online publication of accepted manuscripts as free articles, which will be accessible in PubMed. The Editors and the Editorial Board further commit and expect that ARP will rapidly get an Impact Factor that reflects the quality and value of this journal.
We would like to express our profound gratitude to our dear colleague and friend, Professor Carlos Baena-Cagnani. Carlos conceived and enthusiastically supported the preparation and launching of this journal, which is and will always be a tribute to his memory.
The first publications in ARP include two original research articles and a comprehensive review. The first article reports the findings of a Phase I clinical trial of vitamin D supplementation in patients with cystic fibrosis and allergic bronchopulmonary aspergillosis (ABPA), a condition that causes significant morbidity in patients with asthma [6] . Although preliminary by design, this Phase I trial demonstrates the efficacy of the tested dose of vitamin D (4,000 IU/day) in both achieving vitamin D sufficiency and reducing Th2 immune responses relevant to ABPA and other allergic conditions such as asthma. The second article reports the findings of an Italian questionnaire-based survey about respiratory allergy, as described by patients referred to pharmacists for their symptoms [7] . This aspect is of special interest, since pharmacists are usually the first-line referral. The Authors found that 11 % of patients who accessed pharmacies had only lower respiratory symptoms, but that a large fraction of the population had co-existing upper and lower respiratory symptoms. Notably, about 50 % of patients had not received a medical diagnosis, and thus self-management of repiratory symptoms was common. In spite of the limitations of the questionnaire-based design, those findings highlight the problems of underdiagnosis and under-treatment. The third article reviews current literature on the increasingly common "obese asthma" phenotype, including potential causes, modifiers and common co-morbidities; impact of overweight or obesity on asthma control; growing evidence of distinct endotypes of "obese asthma"; and treatment of patients with co-existing obesity and asthma [8] .
We conclude by inviting all of our esteemed colleagues to submit their work to Asthma Research and Practice, while also welcoming their suggestions to improve the quality and reach of the journal.
